Patients taking the drug trastuzumab deruxecan were 72% less likely to see their cancer grow significantly or to die than those on an existing breast cancer treatment.
Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.
The 2019 ASCO conference news highlights: a year of progress with targeted drugs trialled in prostate, pancreatic, breast and lung cancers.
Older patients with advanced oesophageal and stomach cancers might benefit from low dose treatment, according to our unpublished clinical trial results.
The top stories from the 2018 ASCO annual meeting: overexcited coverage of cancer blood tests and how a gene test can tailor breast cancer treatment.
Our top stories this week: testosterone levels and prostate cancer risk, new cervical screening research and detecting oesophageal cancer earlier.
In our round-up of this year’s NCRI conference we reveal exciting new research that’s helping scientists get to know cancer better.
Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.